Drugs / Ruzasvir
Ruzasvir
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07272889 | Dec 2025 → Feb 2026 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06911320 | Apr 2025 → May 2026 overdue | impaired renal function disease | Atea Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06921941 | Apr → Jul 2025 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06356194 | Apr → May 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06204679 | Dec 2023 → Aug 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05731843 | Jan → Mar 2023 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02666352 | Jan 2016 → Jan 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02661126 | Jan → Aug 2016 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02076100 | Mar 2014 → Nov 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT05904470 | May 2023 → Dec 2024 | chronic hepatitis C virus infection, cirrhosis of liver | Atea Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 2 | NCT02956629 | Nov 2016 → Dec 2017 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02759315 | May 2016 → Jul 2017 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02613403 | Dec 2015 → Jan 2017 | Flaviviridae infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02332720 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02332707 | Jan 2015 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07037277 | Jun 2025 → Dec 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868264 | Apr 2025 → Sep 2026 overdue | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus ateapharma.com ↗
BEM/RZR demonstrated statistical non-inferiority compared to the fixed-dose combination of sofosbuvir and velpatasvir (SOF/VEL) in the modified intent-to-treat (mITT) population, achieving the trial’s primary endpoint. |
| 2026-05-27 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 ateapharma.com ↗
today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. |
| 2026-05-13 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline ateapharma.com ↗
Proton-pump inhibitor omeprazole did not affect the plasma pharmacokinetics of bemnifosbuvir and ruzasvir fixed-dose combination in healthy participants |
| 2025-11-07 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 ateapharma.com ↗
These modeling data will be presented at The Liver Meeting ® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 7-11 in Washington, DC. |
| 2025-05-07 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 ateapharma.com ↗
With a short 8-week treatment duration, the Phase 2 results showed a robust 98% (210/215) sustained virologic response rate at 12 weeks post-treatment (SVR12) with the regimen in the “Per-Protocol Treatment-Adherent Population.” |
| 2024-12-04 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) ateapharma.com ↗
Primary endpoint results demonstrated a 98% (208/213) SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir. |
| 2024-06-05 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 ateapharma.com ↗
With an 8-week treatment duration, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), which is the primary efficacy endpoint of the study. |
| 2024-02-28 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ateapharma.com ↗
I am pleased to share that the 98% SVR4 rate was confirmed in the final results from the lead-in cohort of the Phase 2 combination study. |
| 2024-01-08 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 ateapharma.com ↗
The Company reported positive initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination 8-week study of bemnifosbuvir and ruzasvir (RZR) for the treatment of HCV. |
| 2023-11-13 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 ateapharma.com ↗
Phase 1 data demonstrate that coadministration of bemnifosbuvir and ruzasvir was well tolerated and not affected by food or concomitant dosing, indicating a low risk of drug-drug interactions,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. |
| 2023-11-02 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 ateapharma.com ↗
We are encouraged by the highly potent, pan-genotypic antiviral activity of these compounds, along with the favorable drug-drug interaction and safety profile observed to-date, which supports their use in combination. |
| 2023-03-14 | Atea Pharmaceuticals, Inc. | Results New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research ateapharma.com ↗
Synergistic antiviral effect observed for the combination of bemnifosbuvir and ruzasvir against HCV in vitro |
| 2023-03-08 | Atea Pharmaceuticals, Inc. | Results New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research ateapharma.com ↗
The Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR), the HCV NS5B and NS5A Inhibitors, Demonstrates Potent In Vitro Synergistic Antiviral Activity and In Vivo Preclinical Safety Without Adverse Interactions |
| 2017-04-05 | Merck Sharp & Dohme LLC | Results Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017 merck.com ↗ |
All press releases naming this drug 23 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ruzasvir | “This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir...” NCT02613403 ↗16“A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of a Single Oral Dose of Bemnifosbuvir/Ruzasvir Fixed Dose Combination on the Pharmacokinetics of Digoxin and...” NCT06921941 ↗ “FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.” NCT02661126 ↗ |
| Known as | MK-8408 | “The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) +...” NCT02661126 ↗2“This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection.” NCT02076100 ↗ “ruzasvir (RZR [MK-8408]; 60 mg)” NCT02613403 ↗ |
| Known as | RZR | “In clinical trials, the three-drug regimen of ruzasvir (RZR) 60 mg, uprifosbuvir (UPR) 450 mg and grazoprevir 100 mg, with or without ribavirin, has demonstrated promising...” PMID 30739366 ↗ Mar 20194“A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)” NCT06204679 ↗ “Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination” NCT06911320 ↗ “ruzasvir (RZR [MK-8408]; 60 mg)” NCT02613403 ↗ “Ruzasvir (RZR; AT-038) Capsules” NCT05904470 ↗ |
| Action | Inhibit | “ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day)” PMID 28802814 ↗ Aug 2017 |
| Modality | Other / unclassified | “Ruzasvir (MK-8408, an NS5A inhibitor) and uprifosbuvir (MK-3682, a nonstructural protein 5B nucleotide inhibitor) are highly potent direct-acting antiviral agents” PMID 31108015 ↗ Jul 2019 |
| Route | Oral | “Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.” NCT02076100 ↗ |